Evidence map›Paper›PMID 26392380›Full record

ReviewNature reviews. Neurology2015

Monoamine neurotransmitter disorders--clinical advances and future perspectives.

Joanne Ng, Apostolos Papandreou, Simon J Heales, Manju A Kurian

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06853977 (Understanding the Role of Monoaminergic Neurotransmitters in Cognitive Functions Using Fast-cyclic Voltammetry in Patients With Neurological and Psychiatric Diseases Eligible for Neurosurgical Treatment), which is not on this map. Cited by 117 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 4 pooled it
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06853977 naactive not recruitingnot on this mapstarted 2025, after this paper: background citation

Understanding the Role of Monoaminergic Neurotransmitters in Cognitive Functions Using Fast-cyclic Voltammetry in Patients With Neurological and Psychiatric Diseases Eligible for Neurosurgical Treatment (COGAMINE)

TypeinterventionalSponsorCentre Hospitalier St AnneRan2025 to 2035Enrolled200ConditionsNeurological Diseases or Conditions, Psychiatric Diseases, Candidates for Deep Brain Stimulation, Candidates for Invasive S-EEGArmsCognitive tasks
3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 4 syntheses or guidelines pooled it, 266 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. An LC-MS/MS-based approach for monitoring monoaminergic status in lizard brains: method development and real-samples application.Journal of comparative physiology. A, Neuroethology, sensory, neural, and behavioral physiology · 2025
    Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Joanne NgInstitute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK.
Apostolos PapandreouInstitute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK.
Simon J HealesNeurometabolic Unit, National Hospital, Queen Square, London WC1N 3BG, UK.
Manju A KurianInstitute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK.
University College London · GB

Funding

Medical Research Council MR/K02342X/1Wellcome Trust WT098524MA
6 · The paper itself

Abstract

The monoamine neurotransmitter disorders are important genetic syndromes that cause disturbances in catecholamine (dopamine, noradrenaline and adrenaline) and serotonin homeostasis. These disorders result in aberrant monoamine synthesis, metabolism and transport. The clinical phenotypes are predominantly neurological, and symptoms resemble other childhood neurological disorders, such as dystonic or dyskinetic cerebral palsy, hypoxic ischaemic encephalopathy and movement disorders. As a consequence, monoamine neurotransmitter disorders are under-recognized and often misdiagnosed. The diagnosis of monoamine neurotransmitter disorders requires detailed clinical assessment, cerebrospinal fluid neurotransmitter analysis and further supportive diagnostic investigations. Prompt and accurate diagnosis of neurotransmitter disorders is paramount, as many are responsive to treatment. The treatment is usually mechanism-based, with the aim to reverse disturbances of monoamine synthesis and/or metabolism. Therapeutic intervention can lead to complete resolution of motor symptoms in some conditions, and considerably improve quality of life in others. In this Review, we discuss the clinical features, diagnosis and management of monoamine neurotransmitter disorders, and consider novel concepts, the latest advances in research and future prospects for therapy.

Indexed as

AnimalsBiogenic MonoaminesClinical Trials as TopicHumansNervous System DiseasesNeurotransmitter AgentsBiogenic MonoaminesNeurotransmitter Agents

Identifiers

PMID26392380
OpenAlexW2220929072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.